N/A N=11 Evaluation of Procedural Analgesia for Liposonix Treatment
Body Contouring
Primary: Pain Score for Overall Treatment — 6.3 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=725 Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit/Hyperactivity Disorder
Primary: Change From Baseline of Period 1 (Baseline 1) to End of Period 1 on Attention-Deficit/Hyperactivity Disorder Rating Scale (DSM-IV ADHD RS) Total Score by Treatment…
N/A N=38 Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-way Pagers
Schizophrenia
Primary: Percent of Prescribed Medication Taken as Assessed by the Medication Event Monitoring System (MEMS) — 51.7; 79.0 percentage of prescribed medication take — p=0.083
N/A N=45 Effects of Ghrelin on Alcohol Cue Reactivity and Craving
Alcoholism
Primary: Alcohol Visual Analogue Scale (A-VAS) — 1.95; 2.66; 4.29 units on a scale
Phase 2 N=61 Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients
Type 2 Diabetes Mellitus
Primary: Safety: Adverse Events, Adverse Drug Reactions — 75.0; 66.7; 35.7; 46.2 percentage of incidences
N/A N=71 Clinical Performance Comparison of Several Different Contact Lenses
Myopia
Primary: Limbal Hyperemia (Redness) — 40; 14; 24; 12 eyes
N/A N=59 Comparing the Effectiveness of Two Therapies to Treat Signs of Anorexia Nervosa in Adolescents
Eating Disorders
Primary: Body Mass Index (BMI) Z-score — -0.72; -0.02 z-score
Phase 4 N=76 The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes
Type 2 Diabetes Mellitus
Primary: Reactive Hyperemia Index (RHI) — 1.90; 1.79; 2.24; 1.95 ratio — p=<0.0001
Phase 4 N=57 A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients
Kidney Transplantation, Cytomegalovirus Infections
Primary: Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) or Withdrawal Due to AEs — 56; 41; 6 Participants
Phase 3 N=352 A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy
Hallux Valgus
Primary: Sum of Pain Intensity Differences (SPID) Over 48 Hours — 65.3; 131.7; 154.5 Scores on a scale — p=<0.001
Phase 3 N=381 Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 — -0.76; -0.14 Percent — p=<.001
Phase 3 N=1,299 Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events — 81.8; 82.8; 14.9; 13.3 percentage of incidences
Phase 3 N=447 Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
Non-Hodgkin's Lymphoma · Mantle Cell Lymphoma
Primary: Percentage of Participants With Complete Response (CR) at End of Treatment Period — 31; 25 percentage of participants
Phase 4 N=60 Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
Schizophrenia · Schizoaffective Disorders · Schizophreniform Disorders
Primary: Change in LDL-cholesterol Between Baseline and Week 12 — -25.565; -2.913 mg/dl
Phase 2 N=63 Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)
Inflammation · Rheumatoid Arthritis
Primary: Change in DAS28-CRP After 12 Weeks of Treatment — -1.0; -1.0 scores — p=0.9334